On Friday, Shares of Ford Motor Co. (NYSE:F), lost -0.20% to $15.11.
Ford Motor Company Fund is expanding the Ford College Community Challenge (C3) to Africa, offering universities in four countries the innovative global program that empowers students to improve their communities through sustainability projects.
Ford Fund, the philanthropic arm of Ford Motor Company, will invest more than $100,000 to launch the C3 program in Africa. Under the program, student-led community projects will be chosen in Ghana, Kenya, Morocco and South Africa that address critical local needs and create a more sustainable place to live and work.
“Education is a cornerstone of Ford Fund’s commitment to a better world,” said Jim Vella, president, Ford Motor Company Fund and Community Services. “Through programs like Ford C3, we are able to assist accelerate educational innovation, and empower students to become transformative agents of change in their communities.”
Introduction of the C3 program builds on Ford’s increasing community presence in the Middle East and Africa region.
“As we expand in Africa, we are delivering on our commitment to create a better world by improving the communities where we do business,” said Jim Benintende, president of Ford’s Middle East and Africa (MEA) region.
Ford is collaborating on the program with Enactus, a global NGO that brings together students, academic professionals and business leaders who are committed to using entrepreneurial action to improve lives.
Ford Motor Company manufactures and distributes automobiles worldwide. The company operates through two sectors, Automotive and Financial Services. The Automotive sector develops, manufactures, distributes, and services vehicles, parts, and accessories. It offers vehicles primarily under the Ford and Lincoln brand names.
Shares of American Realty Capital Properties, Inc. (NASDAQ:ARCP), declined -1.97% to $8.47, during its last trading session.
American Realty Capital Properties, declared the appointment of Mark S. Ordan as an Independent Director and a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Company’s Board of Directors effective June 17.
Mr. Ordan presently serves as Executive Chairman of WP Glimcher, the surviving entity following the closing of Washington Prime Group’s acquisition of Glimcher, and will transition to Non-Executive Chairman effective January 1, 2016. WP Glimcher is a retail real estate investment trust (“REIT”) and a recognized leader in the ownership, administration, acquisition and development of mixed use, open-air and enclosed regional malls in addition to community centers. Additionally, Mr. Ordan has been CEO and held various senior-level positions during his 30-year career counting leadership positions at Sunrise Senior Living, The Mills Corporation, Balducci’s gourmet food store chain and Fresh Fields Markets. Mr. Ordan presently serves on the boards of the following nonprofit organizations: the U.S. Chamber of Commerce; the National Endowment for Democracy; the Seed School Foundation; and the Economic Club of Washington, D.C. He received his undergraduate degree from Vassar College and his MBA from Harvard University.
Korn Ferry assisted with the search and placement for Mr. Ordan’s position on the Board.
American Realty Capital Properties, Inc. owns and acquires single tenant, freestanding commercial real estate that is net leased on a medium-term basis, primarily to investment grade credit rated and other creditworthy tenants. The company principally invests in retail and office properties.
Finally, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), ended its last trade with 0.21% gain, and closed at $184.40.
Alexion Pharmaceuticals, declared that it has accepted for exchange all 21,021,124 shares validly tendered into the formerly declared exchange offer by a wholly owned partner of Alexion to acquire all of the outstanding shares of Synageva BioPharma Corp. for the agreed consideration of $115.00 in cash and 0.6581 shares of Alexion common stock for each share of Synageva. The shares accepted represent about 56% of Synageva’s outstanding shares.
The exchange offer expired at midnight, 12:00 a.m., New York City time, at the end of June 19, 2015.
As formerly declared, Alexion will acquire the remaining outstanding shares of Synageva’s common stock through a merger of Synageva with and into a direct wholly owned partner of Alexion, which Alexion anticipates to complete preceding to the opening of trading on NASDAQ Tuesday, June 23, 2015.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
